Nanjing Hicin Pharmaceutical Co., Ltd. (SHE:300584)

China flag China · Delayed Price · Currency is CNY
42.83
+0.92 (2.20%)
At close: Mar 10, 2026
121.00%
Market Cap 5.14B
Revenue (ttm) 615.39M
Net Income (ttm) 44.78M
Shares Out 120.00M
EPS (ttm) 0.37
PE Ratio 114.80
Forward PE n/a
Dividend 0.10 (0.24%)
Ex-Dividend Date n/a
Volume 2,095,134
Average Volume 2,943,683
Open 42.74
Previous Close 41.91
Day's Range 42.38 - 43.01
52-Week Range 15.54 - 81.88
Beta 0.28
RSI 40.78
Earnings Date Apr 25, 2026

About SHE:300584

Nanjing Hicin Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of chemical preparations, APIs, and intermediates. The company’s products include landiolol hydrochloride, rivaroxaban, tigecycline, torasemide, cefuroxime sodium, ceftriaxone hydrochloride, ganciclovir sodium, adenosine monophosphate, and adenosine monophosphate for injection; voglibose tablets, lansoprazole enteric-coated tablets, amlodipine besylate tablets, and glucosamine sulfate effervescent tablets/granules; ... [Read more]

Sector Healthcare
Founded 2003
Employees 548
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300584
Full Company Profile

Financial Performance

In 2024, SHE:300584's revenue was 504.36 million, a decrease of -2.60% compared to the previous year's 517.83 million. Earnings were 40.22 million, an increase of 10.75%.

Financial Statements

News

There is no news available yet.